ProMIS reports interim PRECISE-AD data showing no ARIA-E, ends Q2 with $53.4 million
Blinded six-month safety and biomarker results from the Phase 1b Alzheimer's trial of PMN310 show zero ARIA-E cases, with topline data due in Q1 2027.
SEC filing
Latest
1 story